Use of Predicted Risk and Expected Benefit to Guide Decision-Making in Cardiovascular-Kidney-Metabolic Syndrome for the Primary Prevention of Cardiovascular Disease
Updated: June 09, 2026
- The American Heart Association Predicting Risk of Cardiovascular Disease EVENTs (PREVENT™) equations play a central role in risk assessment and management of cardiovascular-kidney-metabolic (CKM) syndrome.
- The 2026 AHA/ACC/ADA/ASN CKM Guideline recommends the use of the PREVENT equations to (1) define CKM syndrome stage 3, (2) decide when to test for subclinical cardiovascular disease (CVD); and (3) guide risk-based decision making for CKM therapies.
- This AHA/ACC Scientific Statement outlines the rationale for the guideline’s framework for risk and benefit in selecting risk thresholds and provides practice guidance to support clinical implementation and shared decision-making.
Use of Risk, Benefit to Guide Decision-Making in the 2026 CKM Syndrome Guideline
In this video, Writing Group Chair Sadiya S. Khan, MD, MSc introduces a joint American Heart Association and American College of Cardiology scientific statement supporting the 2026 CKM Syndrome Guideline that explains how the PREVENT equations were used to guide patient-centered decision-making, identify those most likely to benefit from therapy, and improve implementation of CKM recommendations in clinical practice. Dr. Khan reviews key PREVENT thresholds, the concept of benefit-based treatment, and practical strategies to support risk communication and guideline adoption, all aiming to advance prevention for patients at risk for cardiovascular disease, kidney disease, and metabolic conditions.